ClinicalTrials.gg
RecruitingNCT06798896Updated Oct 1, 2026

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

A Phase 2 interventional study of SPN-817 and Placebo in Focal Onset Seizures, sponsored by Supernus Pharmaceuticals, Inc.. Recruiting at 63 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.
Updated Oct 1, 2026First sites in 4 new countries62 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
64th of 306
216 · median 56
Started
2024
with 19 others
Phase 2
64 of 395
10 open now
Primary completion
2027-08
later than 39 of 91 live
Registered
363rd of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 64th largest by planned enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2024, is one of 64 in phase 2, reaches primary completion later than 39 of the 91 other live ones, and was the 363rd registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Read the detailed description

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.

03

Conditions studied

  • Focal Onset Seizures

Keywords

  • focal seizures
  • focal epilepsy
  • Phase 2
  • anti-seizure medication
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
  2. Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
  3. Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
  4. Has a (BMI) between 18.0 and 40.0 kg/m2;
  5. Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
  6. At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;

Exclusion criteria

Exclusion Criteria:

  1. Has taken huperzine A within the past 6 months;
  2. Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
  3. History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
  4. Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
  5. History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
  6. History of status epilepticus within 6 months prior to screening;
  7. Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
  8. Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
  9. Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
  10. History of >2 allergic reactions to an ASM or 1 serious reaction to an ASM;
  11. Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    SPN-817

    SPN-817, bid

    Drug: SPN-817

  • Placebo comparator
    Placebo

    Placebo, bid

    Drug: Placebo

Interventions

  • SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

  • DrugPlacebo

    Placebo, bid

06

What researchers measure

Primary outcomes

  1. Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period

    Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline

    Time frame: Baseline and Maintenance Period (Maintenance Week 1-14)

Secondary outcomes

  1. Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline

    Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline.

    Time frame: Baseline and Maintenance Period (Maintenance Week 1-14)

  2. PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period

    Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline

    Time frame: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

  3. Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline

    Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline.

    Time frame: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

  4. Longest seizure-free interval over the entire Treatment Period

    The longest intervals in days between two seizures during the entire Treatment Period.

    Time frame: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

  5. Incidence of treatment-emergent adverse events (TEAEs)

    The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment.

    Time frame: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4

07

Study locations

60 of 63 sites recruiting
  • Xenoscience
    Phoenix, Arizona 85004, United States
    Recruiting
  • Banner University Medical Center-Phoenix
    Phoenix, Arizona 85006, United States
    Recruiting
  • Center for Neurosciences
    Tucson, Arizona 85718, United States
    Recruiting
  • University of Arizona College of Medicine - Tucson
    Tucson, Arizona 85724, United States
    Recruiting
  • Clinical Trials, Inc
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Clinical Research Institute
    Los Angeles, California 90048, United States
    Recruiting
  • Access Community Clinical Trials
    Mission Hills, California 91345, United States
    Recruiting
  • University of California, Irvine
    Orange, California 92868, United States
    Recruiting
  • Focus Clinical Research
    West Hills, California 91307, United States
    Recruiting
  • Yale University
    New Haven, Connecticut 06510, United States
    Recruiting
  • Northwest Florida Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
    Recruiting
  • Ilumina Medical Research
    Kissimmee, Florida 34744, United States
    Recruiting
  • Visionary Investigators Network
    Miami, Florida 33133, United States
    Recruiting
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
  • Research Institute of Orlando, LLC
    Orlando, Florida 32806, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Medsol Clinical Research Center
    Port Charlotte, Florida 33952, United States
    Recruiting
  • Cleveland Clinic Florida Martin Health
    Port Saint Lucie, Florida 34990, United States
    Recruiting
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
    Recruiting
  • University of Louisville Physicians
    Louisville, Kentucky 40223, United States
    Recruiting
  • Neurocare of Louisiana
    Covington, Louisiana 70433, United States
    Recruiting
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
    Recruiting
  • Mid Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
    Recruiting
  • Wayne State University - Detroit Medical Center
    Detroit, Michigan 48201, United States
    Recruiting
  • Northeast Regional Epilepsy Group - Hackensack
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Hackensack Meridian Health Jersey Shore University Medical Center
    Neptune City, New Jersey 07753, United States
    Recruiting
  • Albany Medical Center
    Albany, New York 12208, United States
    Recruiting
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
    Recruiting
  • Northwell Health - Lenox Hill
    New York, New York 10021, United States
    Recruiting
  • University of Rochester Medical Center
    Rochester, New York 14618, United States
    Recruiting
  • Asheville Neurology Specialists
    Asheville, North Carolina 28806, United States
    Recruiting
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Neurology Institute Epilepsy Center of Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
  • Advanced Neurology Epilepsy and Sleep Center/ANESC Research
    El Paso, Texas 79912, United States
    Recruiting
  • Stryde Research
    Frisco, Texas 75034, United States
    Recruiting
  • UT Health Houston
    Houston, Texas 77030, United States
    Recruiting
  • Medstar Health Research Institute
    McLean, Virginia 22101, United States
    Recruiting
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
    Recruiting
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
    Recruiting
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
    Recruiting
  • The Perron Institute for Neurological and Translational Science
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
    Sofia, Sofia-Grad 1431, Bulgaria
    Recruiting
  • Multiprofile Hospital for Active Treatment PULS
    Blagoevgrad, 2700, Bulgaria
    Recruiting
  • Medical Center (MC) Academica
    Pleven, 5809, Bulgaria
    Recruiting
  • Medical Center - Teodora EOOD
    Rousse, 7012, Bulgaria
    Recruiting
  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
    Sofia, 1113, Bulgaria
    Recruiting
  • Flash Clinic
    Budapest, 1125, Hungary
    Recruiting
  • SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
    Budapest, 1145, Hungary
    Recruiting
  • Pratia MCM Kraków
    Krakow, Lesser Poland Voivodeship 30-727, Poland
    Recruiting
  • Centrum Medyczne Plejady
    Krakow, Maloplski 30-363, Poland
    Recruiting
  • Centrum Medyczne NeuroProtect
    Warsaw, Masovian Voivodeship 01-684, Poland
    Recruiting
  • TZ Clinical Research powered by Pratia
    Warsaw, Masovian Voivodeship 02-172, Poland
    Recruiting
  • Neurosphera
    Warsaw, Masovian Voivodeship 02-952, Poland
    Recruiting
  • Synexus Polska Sp. z o. o. Oddział w Gdyni
    Gdynia, Pomeranian Voivodeship 81-537, Poland
    Recruiting
  • Terra Centrum Leczenia
    Sopot, Pomeranian Voivodeship 81-735, Poland
    Suspended

    Not enrolling at this site — choose another above.

  • NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
    Katowice, Silesian Voivodeship 40-123, Poland
    Recruiting
  • Novo-Med Zieliński i Wsp. Sp.J.
    Katowice, Silesian Voivodeship 40-650, Poland
    Recruiting
  • NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
    Lublin, 20-064, Poland
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.

Of 35 phase 2 interventional studies under Seizures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 29, 2025
StartActual
Dec 30, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
62 sites added — first sites in Australia, Bulgaria, Hungary and Poland
Show 62 added (38 United States, 10 Poland, 7 Australia, 5 Bulgaria, 2 Hungary)
  • Xenoscience · Phoenix, United States
  • Banner University Medical Center-Phoenix · Phoenix, United States
  • Center for Neurosciences · Tucson, United States
  • University of Arizona College of Medicine - Tucson · Tucson, United States
  • Clinical Trials, Inc · Little Rock, United States
  • Clinical Research Institute · Los Angeles, United States
  • Access Community Clinical Trials · Mission Hills, United States
  • University of California, Irvine · Orange, United States
  • Focus Clinical Research · West Hills, United States
  • Yale University · New Haven, United States
  • Northwest Florida Clinical Research Group, LLC · Gulf Breeze, United States
  • Ilumina Medical Research · Kissimmee, United States
  • Visionary Investigators Network · Miami, United States
  • University of Miami · Miami, United States
  • Research Institute of Orlando, LLC · Orlando, United States
  • Cleveland Clinic Florida Martin Health · Port Saint Lucie, United States
  • Southern Illinois University School of Medicine · Springfield, United States
  • University of Louisville Physicians · Louisville, United States
  • Neurocare of Louisiana · Covington, United States
  • Ochsner Clinic Foundation · New Orleans, United States
  • Johns Hopkins University · Baltimore, United States
  • Mid Atlantic Epilepsy and Sleep Center · Bethesda, United States
  • Wayne State University - Detroit Medical Center · Detroit, United States
  • Northeast Regional Epilepsy Group - Hackensack · Hackensack, United States
  • Hackensack Meridian Health Jersey Shore University Medical Center · Neptune City, United States
  • Albany Medical Center · Albany, United States
  • Dent Neurologic Institute · Amherst, United States
  • Northwell Health - Lenox Hill · New York, United States
  • University of Rochester Medical Center · Rochester, United States
  • Asheville Neurology Specialists · Asheville, United States
  • …and 32 more on the registry record
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    62 sites added — first sites in Australia, Bulgaria, Hungary and Poland
    Show 62 added (38 United States, 10 Poland, 7 Australia, 5 Bulgaria, 2 Hungary)
    • Xenoscience · Phoenix, United States
    • Banner University Medical Center-Phoenix · Phoenix, United States
    • Center for Neurosciences · Tucson, United States
    • University of Arizona College of Medicine - Tucson · Tucson, United States
    • Clinical Trials, Inc · Little Rock, United States
    • Clinical Research Institute · Los Angeles, United States
    • Access Community Clinical Trials · Mission Hills, United States
    • University of California, Irvine · Orange, United States
    • Focus Clinical Research · West Hills, United States
    • Yale University · New Haven, United States
    • Northwest Florida Clinical Research Group, LLC · Gulf Breeze, United States
    • Ilumina Medical Research · Kissimmee, United States
    • Visionary Investigators Network · Miami, United States
    • University of Miami · Miami, United States
    • Research Institute of Orlando, LLC · Orlando, United States
    • Cleveland Clinic Florida Martin Health · Port Saint Lucie, United States
    • Southern Illinois University School of Medicine · Springfield, United States
    • University of Louisville Physicians · Louisville, United States
    • Neurocare of Louisiana · Covington, United States
    • Ochsner Clinic Foundation · New Orleans, United States
    • Johns Hopkins University · Baltimore, United States
    • Mid Atlantic Epilepsy and Sleep Center · Bethesda, United States
    • Wayne State University - Detroit Medical Center · Detroit, United States
    • Northeast Regional Epilepsy Group - Hackensack · Hackensack, United States
    • Hackensack Meridian Health Jersey Shore University Medical Center · Neptune City, United States
    • Albany Medical Center · Albany, United States
    • Dent Neurologic Institute · Amherst, United States
    • Northwell Health - Lenox Hill · New York, United States
    • University of Rochester Medical Center · Rochester, United States
    • Asheville Neurology Specialists · Asheville, United States
    • …and 32 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06798896
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Dec 30, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Supernus Clinical Trials
Contact
clinicaltrials@supernus.com
240-403-5838
Navid Saeidi, MS
Contact
nsaeidi@supernus.com
240-403-5328
Maciej Gasior, MD, PhD
study director · Supernus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPN-817

Start the discussion